FDA Delays Decision on Novo Hemophilia Drug Over Factory Fixes

The U.S. Food and Drug Administration has extended its review of Novo Nordisk's new hemophilia drug, denecimig, pushing a decision that had been expected in the third quarter of this year into an open-ended wait, according to Fierce Pharma. The Danish drugmaker said the holdup comes down to fixes underway at the factory that will manufacture the medicine, not to problems with the drug itself.

The agency has not set a new date for its decision, and Novo Nordisk says it is working closely with the FDA to clear the outstanding items, according to the company's announcement from October 2, 2026. If approved, the new hemophilia drug would give patients a pen-style injection they could take as rarely as once a month, a schedule designed to fit treatment around daily life rather than the other way around. For now, people living with hemophilia A keep waiting for a choice they expected by now.

Why the FDA review stalled

Novo filed its application for the hemophilia drug in September of 2025, and the company had been expecting a verdict during the third quarter of 2026. After the submission, FDA inspectors visited the manufacturing site in a standard pre-license inspection and handed back feedback that required remediation work, as reported by Nordic Life Science.

The important distinction, Novo says, is that the FDA has not flagged any deficiencies in the clinical efficacy or safety data behind the application. The trial results stand; it is the factory that needs more work. The company stressed that the manufacturing feedback does not affect any of its medicines already on the market, a point it repeated to reassure patients and prescribers alike.

That framing matters because the news lands at a delicate moment for Novo Nordisk. The company's core obesity business has been under pressure from investors this year, and its full-year guidance already anticipates a sales decline. Even so, the company says the delayed hemophilia review will not change its 2026 financial outlook, and it still aims to launch the hemophilia drug in the United States during the first half of next year if the FDA signs off.

What the hemophilia drug does

Denecimig is a lab-made antibody that mimics the missing clotting protein in hemophilia A, a genetic bleeding disorder in which blood cannot clot properly. Sold under the brand name Frehemgo, it would arrive as a prefilled pen injected under the skin either weekly, every two weeks, or monthly, depending on the patient and the doctor's assessment.

That flexibility is the point. Many patients with hemophilia A still manage their condition with intravenous infusions of factor VIII, sometimes several times a week, which is especially tough for young children and their parents. A monthly pen could replace that routine entirely, according to Medical Daily's breakdown of the FDA delay.

The clinical case behind the drug looks strong. In late-stage trials, once-monthly dosing cut treated bleeds by 99 percent compared with on-demand treatment, and a large share of participants went through the study without a single treated bleed. The program also included an extension study and pediatric research, with trials covering adults, adolescents, and children, with or without the inhibitors that can make standard factor therapy stop working.

How it stacks up against the current option

The hemophilia drug would not be the first of its kind. Roche's Hemlibra, which works through a similar clotting mechanism, is already approved and widely used, so denecimig would enter the market as a second option with more dosing choices and a different delivery device. For families, the practical differences may come down to the pen design and the three dosing schedules.

Europe has already given its verdict. The European Medicines Agency's advisory panel recommended approval of the therapy in mid-September, and Saudi Arabia became the first regulator in the world to clear it, according to Hemophilia News Today. Novo expects to launch in the first European countries in the final quarter of 2026, with a wider regional rollout in early 2027.

That contrast is worth noting: the same medicine, cleared abroad and stalled in the United States over factory paperwork. It is a reminder that an FDA review covers far more than trial data, and that a plant inspection can hold up even a drug whose science is not in question.

What happens next for patients

Novo chief executive Mike Doustdar said in the company's statement that people with hemophilia A should expect more from their standard of care, and that the company is addressing the FDA's requests as quickly as it can. The company described the setback as a defined operational issue rather than a scientific one, and analysts who cover the hemophilia drug market expect the story to turn on factory readiness rather than any surprise in the data.

For patients, the practical advice has not changed: continue the current treatment plan and talk with your hemophilia treatment center about options, as doctors quoted in coverage of the delay emphasize. The extended review does not alter what is known about the drug's safety profile from trials, where injection-site reactions were the most common side effect and no blood clots or neutralizing antibodies against the medicine were seen.

The longer-term question is whether denecimig can carve out space against an entrenched rival once it does launch. A second antibody-based therapy would give insurers and clinics leverage, and more dosing choices would let families pick the schedule that fits their lives. First, though, Novo has to finish fixing the factory, and the FDA has to decide when it is satisfied that the hemophilia drug can be made consistently at scale. For a community that has waited years for new options, the delay is measured not just in quarters but in infusions still required every week.

For more coverage of new medicines and the science behind them, see our Health section, and read our recent reporting on how a liquid biopsy is spotting melanoma's return months before scans.